Glaukos Corporation
GKOSHealthcareNASDAQMedical Devices · Last scanned May 30, 2026
Scan Results
Daily timeframeGlaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and. Valued at $6.07B, GKOS is a mid-cap name in its sector. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.
Market Cap
$6.07B
Beta
0.95
P/E (TTM)
—
P/E (Fwd)
215.69
EPS (TTM)
$-3.30
EPS (Fwd)
$0.48
ROE
-26.4%
ROA
-5.8%
Cash
$276.7M
Total Debt
$105.9M
Free CF
$6.1M
52W Change
9.0%
Annual Financials
Cash vs Debt
With $276.7M in cash and $105.9M in debt, GKOS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $6.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -26.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $282.9M (2022) to $507.4M (2025), reflecting a 79% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Glaukos Corporation and its sector.